Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
sodium thiosulfate (DB-020) / Regeneron
ACTRN12620000182998: Phase 1b trial to investigate the prevention of hearing loss in cancer patients receiving cisplatin chemotherapy	Not yet recruiting	1/2	70			Decibel Therapeutics Australia Pty Ltd, Decibel Therapeutics Australia Pty Ltd	Hearing loss (ototoxicity from cisplatin medication)
NCT04262336: Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment	Completed	1b	22	US, RoW	DB-020, Sodium Thiosulfate (STS) pentahydrate formulated in sodium hyaluronate, Placebo, sodium hyaluronate in sodium chloride	Decibel Therapeutics	Ototoxicity	07/22	05/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
sodium thiosulfate (DB-020) / Regeneron
ACTRN12620000182998: Phase 1b trial to investigate the prevention of hearing loss in cancer patients receiving cisplatin chemotherapy	Not yet recruiting	1/2	70			Decibel Therapeutics Australia Pty Ltd, Decibel Therapeutics Australia Pty Ltd	Hearing loss (ototoxicity from cisplatin medication)
NCT04262336: Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment	Completed	1b	22	US, RoW	DB-020, Sodium Thiosulfate (STS) pentahydrate formulated in sodium hyaluronate, Placebo, sodium hyaluronate in sodium chloride	Decibel Therapeutics	Ototoxicity	07/22	05/23